drugset / Trial / NCT02303951
Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of the efficacy, safety and biologic effects of neo-adjuvant treatment with vemurafenib + cobimetinib + atezolizumab in patients with limited metastasis of melanoma in stage IIIC/IV melanoma.
Timeline
- Start
- 2015-01-22
- Primary completion
- 2020-05-14
- Completion
- 2020-05-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 840 mg | Intravenous |
| Subject | Cobimetinib | Small molecule | 60 mg | Oral |
| Subject | Vemurafenib | Small molecule | 720 mg | Oral |